DMAC vs SOFI · $157.4M cap vs P/E 39, rev $619.4M
DiaMedica Therapeutics Inc (DMAC) versus SoFi Technologies Inc. (SOFI) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
SoFi Technologies Inc. (SOFI) is a credit services company listed on NASDAQ.
DMAC does not have a complete income-statement cache yet.
Latest reported SOFI revenue for 2025-12-31 was $619.4M. Net income was $481.3M. Revenue was up 23.1% from 2024-12-31 to 2025-12-31. SOFI currently screens at market cap $22.25B and trailing P/E 38.5.
DMAC currently screens at market cap $157.4M. SOFI currently screens at market cap $22.25B and trailing P/E 38.5.
Not investment advice. Open the DMAC and SOFI stock pages for the full models.
Not investment advice.